Alembic Pharma gains 4% on USFDA nod for key diabetes drug

Alembic Pharma gets USFDA nod for generic Dapagliflozin tablets, equivalent to AstraZenecas Farxiga, gaining 180 day shared exclusivity in a $10.49 billion US market

Leave a Reply

Your email address will not be published. Required fields are marked *